ロード中...
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
Targeting tumor-driven angiogenesis is an effective strategy in the management of metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is complicated by the availability of several drugs, the occurrence of resistance and the lack of validated prognostic and predictive biom...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8141840/ https://ncbi.nlm.nih.gov/pubmed/34041019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.637823 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|